Leadership Question Marks Cloud BioNTech’s First US Cancer Drug Submission
13.06.2026 - 02:54:43 | boerse-global.de
BioNTech is sprinting toward a historic milestone — its first Biologics License Application for a cancer drug — but the stock remains pinned down by a nagging leadership vacuum that has investors reluctant to fully commit. Shares closed the most recent week at €78.25, up 2.09% on the week yet still 5.15% lower year to date and nearly 14% below where they stood twelve months ago. The gap between where the science is heading and where the market prices the equity has rarely been wider.
The BLA filing, planned for later this year with partner DualityBio, targets the antibody-drug conjugate Trastuzumab Pamirtecan (BNT323/DB?1303) for advanced endometrial cancer. The US Food and Drug Administration has already granted fast track and breakthrough therapy designations. Phase?2 data from 145 patients showed a confirmed objective response rate of 47.9%, climbing to 73.1% in those with the highest HER2 expression, and median progression?free survival of 8.1 months. Notably, the drug worked across all HER2 expression levels — a potential first for patients with low expression (IHC?1+ and IHC?2+), who currently lack approved HER2?directed therapy. In China, DualityBio submitted a marketing application in April that has been accepted for review by the NMPA.
Yet even this long?awaited regulatory submission has failed to lift the shares decisively, largely because the company’s founders, Ugur Sahin and Özlem Türeci, plan to step down from their leadership roles by the end of 2026 to establish a separate mRNA company. The announcement sent the stock plunging more than 20% to its lowest level since August?2024, and three months later the wound is slow to heal. The supervisory board is searching for a new CEO and chief medical officer but has disclosed no names. For a biotech whose identity is inseparable from its scientific founders, that is no short?term noise — it is a fundamental uncertainty that will not resolve until a successor is named. The technology transfer to the new venture also remains incomplete, with a binding agreement deadline of end?June?2026 approaching.
Beyond the leadership question, the oncology pipeline continues to generate encouraging signals. Pumitamig demonstrated consistent antitumour activity in combination with chemotherapy for first?line non?small cell lung cancer, while Gotistobart showed durable responses in heavily pretreated patients with platinum?resistant ovarian cancer, offering a potential chemotherapy?free option. The broader oncology programme now spans more than 25 Phase?2 and Phase?3 studies, including 13 registrational trials. The company is methodically transforming from a COVID vaccine supplier into a diversified cancer specialist, but the market is demanding more proof — particularly Phase?3 readouts — before re?rating the stock.
Should investors sell immediately? Or is it worth buying BioNTech?
Financials reflect the transition pain. In the first quarter of 2026, BioNTech posted a net loss of €531.9?million on revenue of €118.1?million, with research and development spending reaching €557?million. Management reiterated full?year revenue guidance of €2.0?2.3?billion but cautioned that no oncology revenue will materialise in 2026; COVID vaccine sales continue to shrink. The company is simultaneously cutting costs: it plans to close manufacturing sites in Idar?Oberstein, Marburg, Tübingen and Singapore by end?2027, exploring partial or complete sales for each, with annual savings of around €500?million expected from 2029.
The bull case rests on a fortress balance sheet. BioNTech holds €16.8?billion in cash and securities — a war chest big enough to fund both pipeline development and a sizeable share buyback programme. After shareholder approval, the company can repurchase up to 24.9?million shares (10% of share capital) through May?2027, a signal that management believes the stock is undervalued at current levels.
Analyst consensus sees a target price of €106.24, implying roughly 36% upside from €78.25. UBS upgraded the stock from Neutral to Buy after the ASCO data, raising its target to $135 and calling the sell?off a buying opportunity. Bernstein’s Jeffrey Walch started coverage at Market Perform with a $96 target, preferring to wait for Phase?3 results. Technically, the shares trade below the 50?day (€81.10), 100?day (€84.40) and 200?day (€85.61) moving averages, with the RSI at 49.2 — neither oversold nor showing signs of a rebound.
BioNTech at a turning point? This analysis reveals what investors need to know now.
BioNTech is not a broken company. It is a company caught between two pivotal events: the imminent FDA filing for its first proprietary cancer drug and an unresolved succession that leaves the market guessing who will steer the ship through the storm. The stock is likely to trade in a range until investors can answer two questions — who will take the helm after Sahin and Türeci, and whether the second?half Phase?3 results will force a revaluation of the oncology pipeline. At €78.25, the risk?reward may draw patient investors, but the leadership void is a real discount that only a concrete successor can close.
Ad
BioNTech Stock: New Analysis - 13 June
Fresh BioNTech information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
